Genmab A/S (OTCMKTS:GNMSF) Sees Large Volume Increase - Still a Buy?

Key Points

• Genmab A/S experienced a significant increase in trading volume, with 4,001 shares traded on Friday, marking a 69% rise from the previous session.
• The company reported earnings per share of $5.42, exceeding analyst estimates of $3.99, although revenue of $925 million fell short of expectations.
• Genmab has a market capitalization of $21.80 billion and specializes in developing antibody therapeutics for cancer and other diseases.

Shares of Genmab A/S (OTCMKTS:GNMSF - Get Free Report) saw strong trading volume on Friday . 4,001 shares traded hands during trading, an increase of 69% from the previous session's volume of 2,361 shares.The stock last traded at $336.45 and had previously closed at $335.77.

Genmab A/S Price Performance

The company has a market capitalization of $21.80 billion, a P/E ratio of 16.57 and a beta of 0.95. The firm's 50-day moving average is $256.77 and its 200-day moving average is $222.12.

Genmab A/S (OTCMKTS:GNMSF - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $5.42 earnings per share for the quarter, topping analysts' consensus estimates of $3.99 by $1.43. Genmab A/S had a net margin of 37.53% and a return on equity of 21.03%. The firm had revenue of $925.00 million during the quarter, compared to analyst estimates of $949.06 million.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.